Palliative effect of interaperitoneal administration of triamcinolone acetonide in patients with malignant peritonitis

Palliative effect of interaperitoneal administration of triamcinolone acetonide in patients with malignant peritonitis - Intraperotoneal administration of Kenacolt

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010233

Enrollment

Registered

2013-03-13

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory patients with malignant peritonitis

Interventions

Triamcinolone acetonide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Refractory malignant peritonitis required the abdoninal puncture over twice per two weeks 2. not indicated patinets with chemotherapy 3. life ecpectancy less than 6 months 4. more than 20 years old 5. Written informed consent

Exclusion criteria

Exclusion criteria: 1. bloody ascitis 2. infectious peritonitis 3. in controlled diabetes mellitus (HbA1c; more than 8.5%) 4. Pregnant or breast feeding woman 5. Not available for follow-up assesments or unable to comply with study

Design outcomes

Primary

Measure	Time frame
Time to the next abdominal puncture	—

Countries

Japan

Contacts

Public ContactHirofumi Katayama

Osaka City General Hospital Dept. of palliative amedicine

ko-takeda@med.osakacity-hp.or.jp06-6929-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026